Following the strong rebound in the S&P at the end of March, are there any compelling investment ideas out there that may have flown under your radar?
Below is a list of April Buy recommendations made by analysts who had no other bullish recommendations over the past 3 months.
For your directory assistance, we've classified the opportunities by sector.
Achieve Life Sciences (ACHV) - ELAM1 Consulting, which focuses on the healthcare sector, says the sell-off could be an opportunity to enter a high-risk, high-reward position, and a DCF analysis suggests a $10 target price upon approval; Cytisinicline demonstrates strong efficacy and a superior safety profile versus Chantix, supporting blockbuster potential in smoking cessation. - Achieve Life Sciences: The Recent Sell-Off Skews The Outcomes (Editor’s note: Shares have rallied since the article was published.).
Universal Health Services (UHS) - Longtime analyst Thomas Lott says it trades at a decade-low valuation despite strong EPS growth and robust capital returns, while significant buybacks, cost controls, and AI-driven efficiencies provide technical and operational support. - Universal Health Services Is A Huge Bargain At 8x Earnings Vs. HCA At 16x.
Regeneron Pharmaceuticals (REGN) - Value investors Derek Pitman & Betsy Yang say the market undervalues the future pipeline and innovation platform amidst competitive and regulatory headwinds while the valuation is revised to $1,230/sh, supported by a 15% FCF growth outlook and strong pipeline execution. - Regeneron: Catching Another Wind.
Eagle Point Credit (ECC) - Longtime analyst ACP Investor says the insider buying event serves as a notable catalyst for investor attention and possible revaluation and that it stands to benefit from the recent reversal in leveraged loan spreads. - Eagle Point Credit: Insiders Are Purchasing While NAV Is In Free Fall.
Anterix (ATEX) - Longtime analyst Fit Investment Ideas
6.11K Followers
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。